## What Lilly’s most recent disclosures imply about a $2.4B “platform-style” pipeline acquisition (engineered circular RNA + proprietary LNP) ### 1) First, the hard check: what Lilly has *actually* disclosed in SEC filings Across the most recent SEC filings available in this workspace (including Lilly’s Q4 2025 results furnished on Form 8‑K and its FY2024 Form 10‑K), I do **not** see any mention of **Orna Therapeutics**, **“circular RNA / circRNA,”** or an engineered circular RNA + proprietary LNP platform by name. (This is based on targeted SEC-filing searches for “Orna” and “circular RNA/circRNA/LNP,” which returned no hits.) So, the only defensible way to “go in depth” from filings is to (a) use Lilly’s disclosed acquisition/accounting pattern, (b) use the company’s own stated posture on BD (“business development”) and “new modalities,” and (c) map what a transaction with the described features would *likely* do to the financial statements and near-term earnings optics—without asserting any un-filed specifics. ### 2) The most “between-the-lines” tell: Lilly is structurally *pre-wiring* investors for recurring acquisition-driven EPS noise Two adjacent disclosures matter more than they look: * **Q4 2025 non-GAAP EPS already includes a large acquired IPR&D addback**, and Lilly explicitly calls out that Q4 results are “inclusive of … acquired IPR&D charges” and quantifies it per share. ["inclusive of $0.52 of acquired IPR&D charges"](0000059478-26-000008|1) * **2026 guidance is explicitly framed to exclude acquired IPR&D incurred after Dec 31, 2025**, which is an unusually direct “don’t anchor on GAAP this year” warning label for acquisition cadence. ["Guidance does not include acquired in-process research and development (IPR&D)"](0000059478-26-000008|1) Read together, the signal is: Lilly expects acquisition-related IPR&D charges to remain a meaningful variable—large enough and frequent enough that they proactively cordon it off from forward-year guidance. That matters for any platform acquisition in early-stage genetic medicine: **if it’s booked as an asset acquisition (not a business combination) and the IPR&D has no alternative future use, the charge can be immediate and large**, impacting GAAP earnings but often treated as non-core by management and many investors. ["any acquired IPR&D that does not have an alternative future use is charged to acquired IPR&D"](0000059478-25-000067|0) ### 3) Why a circular RNA + proprietary LNP “platform” purchase fits Lilly’s *disclosed* acquisition architecture Lilly’s 10‑K is explicit that it uses external deals to “enhance or refine” the pipeline, and it flags that BD in “new modalities” carries incremental risk/cost. ["business development activity focused on new modalities may entail additional risks and costs"](0000059478-25-000067|0) More importantly, the filing lays out the accounting fork that decides whether a deal creates goodwill/intangibles (business combination) versus an immediate IPR&D hit (asset acquisition): * If it’s a **business combination**, you record fair value assets/liabilities and potentially goodwill. ["recorded at their respective fair values"](0000059478-25-000067|0) * If it’s an **asset acquisition**, **no goodwill**, and IPR&D without alternative future use is expensed immediately. ["transaction is recorded as an acquisition of assets"](0000059478-25-000067|0) A platform described as “engineered circular RNA + proprietary LNP” often looks, economically, like **capability + IP + early pipeline** rather than an in-market business. In Lilly’s own framework, that’s exactly the type of fact pattern that can tip toward **asset acquisition treatment**, which is where the “one-time” acquired IPR&D shock lives. ### 4) The financial-statement fingerprint to watch (and why it can create mispricing) If Lilly were to do a large early-stage platform deal, the 10‑K tells you where it will surface: **Income statement (GAAP):** * Expect “Acquired in-process research and development” expense at closing if treated as asset acquisition and no alt future use. ["Acquired in-process research and development (Note 3)"](0000059478-25-000067|0) **Cash flow statement (investing):** * It may show up as “Purchases of in-process research and development” (not necessarily “Cash paid for acquisitions”). ["Purchases of in-process research and development"](0000059478-25-000067|0) **Why this matters for alpha:** many market participants lazily map *all* deal cash spend to “acquisitions” and miss that Lilly’s cash flow line item for IPR&D purchases is already multi‑billion and recurring—so a big platform deal can be **hiding in plain sight as a continuation of a pattern**, not a regime shift. For context, Lilly reported **$3.2804B of acquired IPR&D charges in 2024** and explains the drivers. ["Acquired in-process research and development"](0000059478-25-000067|0) ["primarily related to the acquisition of Morphic"](0000059478-25-000067|0) And the **cash paid** mapped similarly in its liquidity discussion. ["We paid $3.35 billion in 2024 for acquired IPR&D"](0000059478-25-000067|0) So, if investors anchor on “R&D is 20% of revenue” while ignoring that Lilly can *also* externalize R&D via acquisition-driven IPR&D charges, they will systematically under-model GAAP volatility and sometimes overreact to it. ### 5) Strategic logic Lilly itself has disclosed: this is about maintaining replacement power, not “one more program” Lilly explicitly says long-term success depends on the ability to “discover or acquire” and commercialize innovative medicines, and it emphasizes BD as a pipeline tool. ["continually discover or acquire"](0000059478-24-000065|0) ["business development activity as a way to enhance or refine our pipeline"](0000059478-25-000067|0) In that context, a circular RNA + LNP capability is best understood (strategically) as an attempt to buy **optionality on a modality**, not just a single asset: * It can diversify the “shot on goal” mix versus small molecules/antibodies. * It can be a hedge against modality disruption (Lilly explicitly warns that “new or superior modalities” can erode existing product economics). ["new or superior modalities"](0000059478-25-000067|0) * It can import specialized know-how and potentially an “engine” for multiple candidates—exactly the type of “new modalities” BD the risk factors call out. ["new modalities"](0000059478-25-000067|0) ### 6) The underappreciated constraint: platform deals are only as valuable as the *industrialization path* (and Lilly is telling you manufacturing is a gating factor) The “platform” narrative often ignores the bottleneck: scaling and supply. Lilly’s 10‑K is unusually direct that shifting/adding capacity is lengthy, capital intensive, and regulatory-heavy—and that demand can exceed production (they cite this for incretins). ["demand for our incretin medicines exceeded production"](0000059478-25-000067|0) ["Shifting or adding manufacturing capacity is a very lengthy process"](0000059478-25-000067|0) For RNA/LNP and cell-therapy-adjacent approaches, industrialization (process, QC, release assays, supply chain) is frequently where timelines slip. The filings don’t mention circular RNA specifically—but they do telegraph that **manufacturing execution is a board-level issue at Lilly**, which should shape how you handicap any new complex modality program. ### 7) A practical monitoring checklist for the next 1–2 quarters (purely from how Lilly reports) If/when a transaction like the one described is reflected in SEC filings, the fastest way to confirm and size it (often before the market fully digests it) is to watch for: 1) **A step-change in “Acquired IPR&D” expense** on the income statement (GAAP). ["Acquired in-process research and development"](0000059478-25-000067|0) 2) **A corresponding spike in “Purchases of in-process research and development”** in investing cash flows. ["Purchases of in-process research and development"](0000059478-25-000067|0) 3) **MD&A / Note 3 “Acquisitions” narrative** describing the counterparty, whether it’s an asset acquisition vs business combination, and the valuation inputs (probability of technical success, discount rate). ["probability of technical success"](0000059478-25-000067|0) 4) **Non-GAAP reconciliation commentary** that quantifies deal-related charges (like the $0.52/sh acquired IPR&D in Q4 2025). ["acquired IPR&D charges of $0.52"](0000059478-26-000008|1) 5) **Any shift in guidance language** around items that are “not reasonably accessible” to forecast (often code for upcoming deal impacts). ["cannot reasonably predict certain items"](0000059478-26-000008|1) --- ### Bottom line (the “striking” part that tends to get missed) Even without a named disclosure in the filings here, Lilly’s own reporting choices show a repeatable playbook: **they are using acquisitions as an extension of R&D**, and they are conditioning investors to evaluate performance on a basis that *systematically looks through* acquired IPR&D—even while acknowledging those charges can be large and recurring. ["business development activity"](0000059478-25-000067|0) ["inclusive of $0.52 of acquired IPR&D charges"](0000059478-26-000008|1) ["Guidance does not include acquired ... IPR&D"](0000059478-26-000008|1) That combination (steady external pipeline build + GAAP noise + guided non-GAAP framing) is exactly the terrain where mispricings happen: the market often trades the headline charge, while the more durable signal is **whether the acquired modality is becoming a repeatable “engine”** and how quickly it can be industrialized inside Lilly’s manufacturing reality. ["new modalities"](0000059478-25-000067|0) ["Shifting or adding manufacturing capacity"](0000059478-25-000067|0)

## What Lilly’s most recent disclosures imply about a $2.4B “platform-style” pipeline acquisition (engineered circular RNA + proprietary LNP) ### 1) First, the hard check: what Lilly has *actually* disclosed in SEC filings Across the most recent SEC filings available in this workspace (including Lilly’s Q4 2025 results furnished on Form 8‑K and its FY2024 Form 10‑K), I do **not** see any mention of **Orna Therapeutics**, **“circular RNA / circRNA,”** or an engineered circular RNA + proprietary LNP platform by name. (This is based on targeted SEC-filing searches for “Orna” and “circular RNA/circRNA/LNP,” which returned no hits.) So, the only defensible way to “go in depth” from filings is to (a) use Lilly’s disclosed acquisition/accounting pattern, (b) use the company’s own stated posture on BD (“business development”) and “new modalities,” and (c) map what a transaction with the described features would *likely* do to the financial statements and near-term earnings optics—without asserting any un-filed specifics. ### 2) The most “between-the-lines” tell: Lilly is structurally *pre-wiring* investors for recurring acquisition-driven EPS noise Two adjacent disclosures matter more than they look: * **Q4 2025 non-GAAP EPS already includes a large acquired IPR&D addback**, and Lilly explicitly calls out that Q4 results are “inclusive of … acquired IPR&D charges” and quantifies it per share. ["inclusive of $0.52 of acquired IPR&D charges"](0000059478-26-000008|1) * **2026 guidance is explicitly framed to exclude acquired IPR&D incurred after Dec 31, 2025**, which is an unusually direct “don’t anchor on GAAP this year” warning label for acquisition cadence. ["Guidance does not include acquired in-process research and development (IPR&D)"](0000059478-26-000008|1) Read together, the signal is: Lilly expects acquisition-related IPR&D charges to remain a meaningful variable—large enough and frequent enough that they proactively cordon it off from forward-year guidance. That matters for any platform acquisition in early-stage genetic medicine: **if it’s booked as an asset acquisition (not a business combination) and the IPR&D has no alternative future use, the charge can be immediate and large**, impacting GAAP earnings but often treated as non-core by management and many investors. ["any acquired IPR&D that does not have an alternative future use is charged to acquired IPR&D"](0000059478-25-000067|0) ### 3) Why a circular RNA + proprietary LNP “platform” purchase fits Lilly’s *disclosed* acquisition architecture Lilly’s 10‑K is explicit that it uses external deals to “enhance or refine” the pipeline, and it flags that BD in “new modalities” carries incremental risk/cost. ["business development activity focused on new modalities may entail additional risks and costs"](0000059478-25-000067|0) More importantly, the filing lays out the accounting fork that decides whether a deal creates goodwill/intangibles (business combination) versus an immediate IPR&D hit (asset acquisition): * If it’s a **business combination**, you record fair value assets/liabilities and potentially goodwill. ["recorded at their respective fair values"](0000059478-25-000067|0) * If it’s an **asset acquisition**, **no goodwill**, and IPR&D without alternative future use is expensed immediately. ["transaction is recorded as an acquisition of assets"](0000059478-25-000067|0) A platform described as “engineered circular RNA + proprietary LNP” often looks, economically, like **capability + IP + early pipeline** rather than an in-market business. In Lilly’s own framework, that’s exactly the type of fact pattern that can tip toward **asset acquisition treatment**, which is where the “one-time” acquired IPR&D shock lives. ### 4) The financial-statement fingerprint to watch (and why it can create mispricing) If Lilly were to do a large early-stage platform deal, the 10‑K tells you where it will surface: **Income statement (GAAP):** * Expect “Acquired in-process research and development” expense at closing if treated as asset acquisition and no alt future use. ["Acquired in-process research and development (Note 3)"](0000059478-25-000067|0) **Cash flow statement (investing):** * It may show up as “Purchases of in-process research and development” (not necessarily “Cash paid for acquisitions”). ["Purchases of in-process research and development"](0000059478-25-000067|0) **Why this matters for alpha:** many market participants lazily map *all* deal cash spend to “acquisitions” and miss that Lilly’s cash flow line item for IPR&D purchases is already multi‑billion and recurring—so a big platform deal can be **hiding in plain sight as a continuation of a pattern**, not a regime shift. For context, Lilly reported **$3.2804B of acquired IPR&D charges in 2024** and explains the drivers. ["Acquired in-process research and development"](0000059478-25-000067|0) ["primarily related to the acquisition of Morphic"](0000059478-25-000067|0) And the **cash paid** mapped similarly in its liquidity discussion. ["We paid $3.35 billion in 2024 for acquired IPR&D"](0000059478-25-000067|0) So, if investors anchor on “R&D is 20% of revenue” while ignoring that Lilly can *also* externalize R&D via acquisition-driven IPR&D charges, they will systematically under-model GAAP volatility and sometimes overreact to it. ### 5) Strategic logic Lilly itself has disclosed: this is about maintaining replacement power, not “one more program” Lilly explicitly says long-term success depends on the ability to “discover or acquire” and commercialize innovative medicines, and it emphasizes BD as a pipeline tool. ["continually discover or acquire"](0000059478-24-000065|0) ["business development activity as a way to enhance or refine our pipeline"](0000059478-25-000067|0) In that context, a circular RNA + LNP capability is best understood (strategically) as an attempt to buy **optionality on a modality**, not just a single asset: * It can diversify the “shot on goal” mix versus small molecules/antibodies. * It can be a hedge against modality disruption (Lilly explicitly warns that “new or superior modalities” can erode existing product economics). ["new or superior modalities"](0000059478-25-000067|0) * It can import specialized know-how and potentially an “engine” for multiple candidates—exactly the type of “new modalities” BD the risk factors call out. ["new modalities"](0000059478-25-000067|0) ### 6) The underappreciated constraint: platform deals are only as valuable as the *industrialization path* (and Lilly is telling you manufacturing is a gating factor) The “platform” narrative often ignores the bottleneck: scaling and supply. Lilly’s 10‑K is unusually direct that shifting/adding capacity is lengthy, capital intensive, and regulatory-heavy—and that demand can exceed production (they cite this for incretins). ["demand for our incretin medicines exceeded production"](0000059478-25-000067|0) ["Shifting or adding manufacturing capacity is a very lengthy process"](0000059478-25-000067|0) For RNA/LNP and cell-therapy-adjacent approaches, industrialization (process, QC, release assays, supply chain) is frequently where timelines slip. The filings don’t mention circular RNA specifically—but they do telegraph that **manufacturing execution is a board-level issue at Lilly**, which should shape how you handicap any new complex modality program. ### 7) A practical monitoring checklist for the next 1–2 quarters (purely from how Lilly reports) If/when a transaction like the one described is reflected in SEC filings, the fastest way to confirm and size it (often before the market fully digests it) is to watch for: 1) **A step-change in “Acquired IPR&D” expense** on the income statement (GAAP). ["Acquired in-process research and development"](0000059478-25-000067|0) 2) **A corresponding spike in “Purchases of in-process research and development”** in investing cash flows. ["Purchases of in-process research and development"](0000059478-25-000067|0) 3) **MD&A / Note 3 “Acquisitions” narrative** describing the counterparty, whether it’s an asset acquisition vs business combination, and the valuation inputs (probability of technical success, discount rate). ["probability of technical success"](0000059478-25-000067|0) 4) **Non-GAAP reconciliation commentary** that quantifies deal-related charges (like the $0.52/sh acquired IPR&D in Q4 2025). ["acquired IPR&D charges of $0.52"](0000059478-26-000008|1) 5) **Any shift in guidance language** around items that are “not reasonably accessible” to forecast (often code for upcoming deal impacts). ["cannot reasonably predict certain items"](0000059478-26-000008|1) --- ### Bottom line (the “striking” part that tends to get missed) Even without a named disclosure in the filings here, Lilly’s own reporting choices show a repeatable playbook: **they are using acquisitions as an extension of R&D**, and they are conditioning investors to evaluate performance on a basis that *systematically looks through* acquired IPR&D—even while acknowledging those charges can be large and recurring. ["business development activity"](0000059478-25-000067|0) ["inclusive of $0.52 of acquired IPR&D charges"](0000059478-26-000008|1) ["Guidance does not include acquired ... IPR&D"](0000059478-26-000008|1) That combination (steady external pipeline build + GAAP noise + guided non-GAAP framing) is exactly the terrain where mispricings happen: the market often trades the headline charge, while the more durable signal is **whether the acquired modality is becoming a repeatable “engine”** and how quickly it can be industrialized inside Lilly’s manufacturing reality. ["new modalities"](0000059478-25-000067|0) ["Shifting or adding manufacturing capacity"](0000059478-25-000067|0)